Search This Blog

Biopharma Over Coffee

Updates on recent goings on in the pharma, biotech and healthcare sectors.

Posts

Showing posts with the label SCLC

Show all

July 10, 2026

EU Joint Clinical Assessment after the first reports: How should companies interpret the findings?

Get link
Facebook
X
Pinterest
Email
Other Apps

Older Posts Home

Powered by Blogger

Doug Niven: Each week, an article will cover something that you may have missed in the pharma, biotech or healthcare news, and perfect to read over a cup of coffee.

Visit profile

Followers

Labels

10 year plan1
3D Printing1
ABPI1
Access1
Acumen2
adagrasib2
Adaptimmune1
AIFA1
alpha synuclein2
ALS2

Alzheimer's Disease4
Amlyx1
AMX00351
amyloid beta2
antimicrobials1
Artificial Intelligence1
AskBio2
ATMP3
Bayer2
Bial2
Biogen1
biomarkers2
biotech1
Cat-C1
Cell and Gene Therapy2
china1
CIPM1
clinical development3
clinical effectiveness1
clinical studies6
CMS2
cochrane1
colorectal cancer2
Commercial Insurance1
commercialisation1
commercialization3
consumer1
cost effectiveness1
decentralized manufacturing1
Disease Modifying Therapies2
Distal Genes2
Donald Trump2
donanemab4
drug approval2
Drug Assessment1
drug development7
Drug Discovery1
drug pricing12
Drug Repurposing2
Drug Supply2
EFPIA1
Eisai1
Eli Lilly2
EMA5
England1
EPF1
EU1
European Commission1
European Parliament1
European Union3
Executive Order1
Fabhalta2
FDA9
G-BA2
GBA2
genetic medicine1
Genome1
global rebalancing1
GLP-12
GLP-1R2
HAS2
health economics2
Health Technology Assessment3
HEOR1
HTA8
IBD1
Ibudilast1
ICER3
Immuno-oncology1
Inflammation2
Inflammatory Bowel Disease2
international reference pricing1
ION3631
JCA3
Joint Clinical Assessment3
Kinase Inhibitors2
KISUNLA1
KISUNLI2
KRAS mutations2
KRAZATI2
lecanemab4
LEQEMBI3
life sciences plan1
liver disease1
loss of exclusivity1
LUMAKRAS2
Machine Learning1
macitinib1
Macrophages1
manufacturing1
market access10
Market Exclusivity1
MASH1
medicaid1
medical information1
medicare1
MFN3
mild cognitive impairment1
most favored nation1
MOUNJARO1
neuroprotection2
NHS1
NICE4
Novartis3
NRDL1
NSCLC2
obesity1
oncology4
Orphan Drugs5
OZEMPIC1
pancreatic cancer2
Parkinson's Disease2
payers1
Personalised therapy1
personalization1
pharma2
pharmaceuticals2
Pharmaceuticals Legislation1
Pharmacy1
PICO2
pipeline1
PNH2
price negotiations1
pricing2
Prime C1
rare diseases6
real world evidence1
Regulation1
regulatory3
regulatory affairs1
regulatory pathway2
reimbursement8
RELYVIRO1
REZDIFFRA1
Roche2
RWE1
scenario planning1
SCLC1
Single National Formulary1
SMC1
sotorasib1
SPRITAM1
supply chain1
Synovial Sarcoma1
T Cell Therapy1
tariffs3
TECELRA1
Triastek1
UK1
US1
VPAG1
WEGOVY2
weight loss1
ZEPBOUND1

Show more Show less